Among them is first-in-class anti-CD40 antibody iscalimab (CFZ533), which showed in a study reported this summer that it may ... including IgA nephropathy, idiopathic membranous nephropathy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback